The aim of our study was to assess the recurrence and survival of pT1abN0 HER2+ breast cancer patients across different types of treatments and hormone receptor types, using data from the nationwide breast cancer registry, to provide information on possible treatment options to the healthcare providers. The gene discussed is NR4A1; the disease is breast carcinoma.